Results 41 to 50 of about 3,808 (77)

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. [PDF]

Intern Med J
Anderson MA, Awan FT, Berkahn L, Crassini K, Lee HP, Marlton P, Mulligan SP, Nolan M, Tam C, Sverdlov AL.   +9 more
europepmc   +1 more source

Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage. [PDF]

Theranostics
Hao H, Yin T, Li T, Zhou X, Ren H, Liu M, Huang H, Qi C, Xiu Y, Qiu W, Wang D, Shi M, Wang X, Dumont AS, Liu Q.   +14 more
europepmc   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]

ChemMedChem
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W.   +5 more
europepmc   +1 more source

Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures". [PDF]

ACS Pharmacol Transl Sci
Darragh AC, Hanna AM, Lipner JH, King AJ, Servant NB, Jahic M.   +5 more
europepmc   +2 more sources

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events. [PDF]

Cancer Med
Obeng-Kusi M, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, Jiao W, Hyatt HW, Zhang X, Lodaya K, Dingli D.   +10 more
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease. [PDF]

Molecules
Ye Q, Ma S.
europepmc   +1 more source

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Hematol
Buchrits S, Trieman G, Giladi O, Hofstetter L, Gurion R, Granot G, Shacham-Abulafia A, Raanani P, Gafter-Gvili A.   +8 more
europepmc   +1 more source

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. [PDF]

Cureus
Pradhan A, Panchal HP.
europepmc   +1 more source